Juno Therapeutics Inc. on Thursday said it bought privately held, Boston-based RedoxTherapies, Inc. for an undisclosed amount, getting access to a RedoxTherapies' blocker with potential to be used in certain cancer treatments. RedoxTherapies founder Michail Sitkovsky will become a scientific consultant to Juno, the company said. Shares of Juno rose 0.1% in late trading after ending the regular trading session down 5.2%.
Copyright © 2016 MarketWatch, Inc.
Continue Reading Below